Skip to content

PanACEA

  • Contact us
  • Twitter
  • News
  • About Us
    • Mission
    • History
    • Governance
    • Donors
    • Scientific Network
  • Tuberculosis
    • Impact
    • Treatment
    • Drug development
  • Clinical Studies
    • Trial Design
    • PanACEA Studies
    • Vision for future Studies
  • Capacity Development

PanACEA-SUDOCU-01 publication in the Lancet Infectious Diseases 08 July 2025

PanACEA-SUDOCU-01 was a phase 2b clinical trial conducted at four locations in Tanzania and South Africa. The innovative study design allowed administration of a novel backbone of bedaquiline–delamanid–moxifloxacin alone and together with four sutezolid doses (ranging from 600 mg once daily to 800 mg twice daily) to 75 adults with drug-susceptible pulmonary tuberculosis for 12…

Read more PanACEA-SUDOCU-01 publication in the Lancet Infectious Diseases 08 July 2025

Podcast on TB drug development with Lilian Tina Minja and Norbert Heinrich for the Lancet

The Lancet Infectious Diseases in conversation with Lilian Tina Minja and Norbert Heinrich on TB drug development Lilian Tina Minja and Norbert Heinrich discuss the SUDUCO and DECODE trials in The Lancet Infectious Diseases on two new promising TB drugs, sutezolid and delpazolid, respectively. They also discuss the wider implications of the findings of these trials for…

Read more Podcast on TB drug development with Lilian Tina Minja and Norbert Heinrich for the Lancet

Dr Jodie Schildkraut

Radboudumc
Nijmegen, the Netherlands

Read more Dr Jodie Schildkraut

Dr. Laura Paramo MD

Ludwig Maximilian University Munich, Germany

Read more Dr. Laura Paramo MD

Staggered dosing of rifampicin using to minimise tolerability problems and maximize efficacy

PanACEA team together with collaborators at Uppsala University recently published a model-based study further elucidating how to optimally dose rifampicin. The work suggest that a staggered approach, starting a bit lower and then increasing doses, may improve the tolerability for patients and thereby enable the higher doses which we demonstrated earlier is beneficial in terms…

Read more Staggered dosing of rifampicin using to minimise tolerability problems and maximize efficacy

SUDOCU headline results presented at CROI

On Tuesday 20 February 2023 our PanACEA colleague Dr Norbert Heinrich presented the headline-results from the PanACEA SUDOCU study at the 30th Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle – the largest and most important conference on  HIV and related conditions such as tuberculosis. SUDOCU investigated safety and efficacy of varying doses of…

Read more SUDOCU headline results presented at CROI

Ivan Noreña MD, MSc.

Ludwig Maximilians University
Munich, Germany

Read more Ivan Noreña MD, MSc.

PanACEA & SimpliciTB Annual Meeting, Mangochi, Malawi, 20th-22nd September 2022

Finally, after 2 years due to COVID-19, the PanACEA and SimpliciTB family were reunited in Malawi, hosted by Dr Marriott Nliwasa, Kamuzu University of Health Sciences at Makokola Retreat, Mangochi.  The hospitality and organisation of all of the teams made it  a very successful and enjoyable meeting. PanACEA The first day started with a variety…

Read more PanACEA & SimpliciTB Annual Meeting, Mangochi, Malawi, 20th-22nd September 2022

Dr med vet Andrea Kelly

Ludwig Maximilian University
Munich, Germany

Read more Dr med vet Andrea Kelly

Johann de Bruyn

TASK
Cape Town, South Africa

Read more Johann de Bruyn

Posts navigation

← Older posts
© PanACEA
  • edctp
  • European Union
  • This project is part of the
    EDCTP2 programme supported
    by the European Union

  • Contact us
  • Twitter